Stock HXL HEXIMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Hexima Limited Stock

Equities

HXL

AU0000111932

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:10 2024-04-22 EDT 		5-day change 1st Jan Change
0.013 AUD 0.00% Intraday chart for Hexima Limited 0.00% -27.78%
03-22 Hexima Secures R&D Tax Rebate for Fiscal Year 2023 MT
03-19 Hexima Changes Address MT

Financials

Sales 2022 5.81M 3.8M 5.18M Sales 2023 1.48M 970K 1.32M Capitalization 3.51M 2.29M 3.13M
Net income 2022 -10M -6.53M -8.92M Net income 2023 -1M -653K -892K EV / Sales 2022 0.18 x
Net cash position 2022 3.96M 2.58M 3.53M Net cash position 2023 2.19M 1.43M 1.95M EV / Sales 2023 0.89 x
P/E ratio 2022
-0.46 x
P/E ratio 2023
-1.83 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 36.17%
More Fundamentals * Assessed data

Chart Hexima Limited

Dynamic Chart

Latest news about Hexima Limited

Hexima Secures R&D Tax Rebate for Fiscal Year 2023 MT
Hexima Changes Address MT
Hexima Limited Announces Change of Address CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director CI
Hexima Limited Appoints Phillip Hains as A Non-Executive Director CI
Hexima Limited Appoints Geoffrey Kempler as Managing Director CI
Hexima Limited Announces Executive Changes CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Hexima Limited Declares Voting Results CI
Arovella Therapeutics Appoints COO MT
Hexima Acting CEO to Step Down MT
Nicole Van Der Weerden to Step Down as CEO of Hexima Limited CI
More news

Press releases Hexima Limited

Hexima : 2022 Annual Financial Report PU
Hexima : Quarterly Activities Report and Appendix 4C - Jun-22 Qtr PU
Hexima : ShareCafe Presentation PU
Hexima : Notification regarding unquoted securities - HXL PU
Hexima : Investor Webinar on Today PU
More press releases

Quotes and Performance

Current month+8.33%
1 month+8.33%
3 months-27.78%
6 months-40.91%
Current year-27.78%
More quotes

Highs and lows

1 week
0.01
Extreme 0.013
0.01
1 month
0.01
Extreme 0.01
0.01
Current year
0.01
Extreme 0.01
0.02
1 year
0.01
Extreme 0.01
0.02
3 years
0.01
Extreme 0.009
0.50
5 years
0.01
Extreme 0.009
0.50
10 years
0.01
Extreme 0.009
0.50
More quotes

Managers and Directors - Hexima Limited

Managers TitleAgeSince
Geoffrey Kempler CEO
 Chief Executive Officer 69 23-09-04
Leanne Ralph SEC
 Corporate Secretary - 21-10-05
Members of the board TitleAgeSince
Geoffrey Kempler CEO
 Chief Executive Officer 69 23-09-04
Phillip Hains BRD
 Director/Board Member 64 23-09-17
Zhen Nan Yap BRD
 Director/Board Member - 18-07-16
More insiders

Quotes

Date Price Change Volume
24-04-22 0.013 0.00% 761,801

Delayed Quote Australian S.E., April 22, 2024 at 02:10 am

More quotes

Company Profile

Hexima Limited is an Australia-based company. The Company is exploring opportunities for transactions with third parties which could enable the potential value of the Company’s assets, including its intellectual property and other intangible assets, to be realized.
Sector
Biotechnology & Medical Research
Calendar
2024-08-27 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HEXIMA LIMITED Stock Hexima Limited
-27.78% 1.42M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. HXL Stock